Prof. Yun Fan 范云
Chief Physician, Professor
Department of Medical Oncology for Thoracic Tumors, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, targeted therapy, immunotherapy, and palliative care for lung cancer, esophageal cancer, and mediastinal tumors.
Dr. Fan is Chief Physician, Professor, and Director of the Department of Thoracic Medical Oncology at Zhejiang Cancer Hospital, with over 30 years of experience. Dr. Fan has published more than 60 academic papers, including over 30 indexed in SCI, and contributed to four monographs. Dr. Fan leads and participates in multiple international and domestic multicenter clinical studies.
Professional roles
- Council Member, Chinese Society of Clinical Oncology (CSCO)
- Member, Lung Cancer Professional Committee, China Anti-Cancer Association
- Vice Chair, CSCO Small Cell Lung Cancer Expert Committee
- Chair, Tumor Precision Treatment Professional Committee, Zhejiang Medical Doctor Association
Name order: in Chinese the family name comes first (Fan Yun). Papers usually list the name as Yun Fan or Fan Y.
Selected publications
214 papers on PubMed matched by name and affiliation; 78 as first or senior author since 2016. Most recent first- or senior-author papers:
- Transl Lung Cancer Res, 2026 (senior author): Genomic characteristics, survival, and prognostic analysis of advanced non-small cell lung cancer with KRAS mutations and brain metastases. PubMed 42999419
- Lancet Respir Med, 2026 (first author): Amivantamab, lazertinib, and bevacizumab: a chemotherapy-free option for patients with advanced EGFR-mutant NSCLC with acquired resistance to a third-generation EGFR TKI. PubMed 42833237
- Transl Lung Cancer Res, 2026 (senior author): Increasing incidence and improved survival of leptomeningeal metastasis in advanced lung cancer: a 10-year real-world cohort study. PubMed 42723807
- Front Immunol, 2026 (first author): Safety and efficacy of first-line iparomlimab and tuvonralimab (QL1706) plus carboplatin and etoposide in patients with extensive-stage small cell lung cancer: an open-label, single-arm, phase 2 trial (DUBHE-L-209). PubMed 42643500
- J Thorac Oncol, 2026 (first author): First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and Programmed Death-Ligand 1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial. PubMed 41796863
- Int J Cancer, 2026 (senior author): Tislelizumab plus sitravatinib or anlotinib as maintenance therapy in extensive-stage small-cell lung cancer: Results of two prospective phase II studies. PubMed 41195833
- Cancer Treat Rev, 2026 (senior author): Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody-Drug conjugates. PubMed 41604872
- JAMA Oncol, 2026 (senior author): Details Regarding Pneumonitis With High-Dose Aumolertinib-Reply. PubMed 41264304
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion